Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Trial Profile

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SL 701 (Primary) ; Bevacizumab; Poly ICLC
  • Indications Glioblastoma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 15 Mar 2019 According to a Stemline Therapeutics media release, the company expect to provide further updates on this study later this year.
    • 02 Jan 2019 According to a Stemline Therapeutics media release, recent data from this study were presented at the Society for Neuro-Oncology (SNO) annual conference.
    • 16 Nov 2018 According to a Stemline Therapeutics media release, data from this trial will be presented at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO) being held November 15-18, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top